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Potentiation of temozolomide and BCNU cytotoxicity by
06-benzylguanine: a comparative study in vitro
SR Wedge, JK Porteous, BL May and ES Newlands
Department ofMedical Oncology, Charing Cross Hospital, Fulham Palace Road, London W6 8RF, UK.
Summary Depletion of the DNA repair protein 06-alkylguanine-DNA alkyltransferase (AGT) with o6_
benzylguanine (06-BG) has been widely shown to enhance 1,3-bis(2-chloroethyl)-nitrosourea (BCNU) activity.
This study aimed to determine whether temozolomide, a methylating imidazotetrazinone, would similarly
benefit from combination with 06-BG. Seven human cell lines were examined with AGT activities ranging from
< 6 fmol mg'-I protein to >700 fmol mg'- protein. Comparisons with BCNU were made on both single and
multiple dosing schedules, since temozolomide cytotoxicity is highly schedule dependent. In single-dose
potentiation studies, cells were preincubated with 100 MM 06-BG for 1 h, a treatment found to deplete AGT
activity by >90% for 24 h. No potentiation of either temozolomide or BCNU cytotoxicity was observed in
two glioblastoma cell lines with <6 fmol mg-' protein AGT. In all other cell lines studied potentiation of
BCNU cytotoxicity by 06-BG was between 1.6- and 2.3-fold and exceeded that of temozolomide (1.1- to 1.7-
fold). The magnitude of this potentiation was unrelated to AGT activity and the relative potentiation of
temozolomide and BCNU cytotoxicity was found to be highly variable between cell lines. In multiple dosing
studies two colorectal cell lines (Mawi and LS174T) were treated with temozolomide or BCNU at 24 h
intervals for up to 5 days, with or without either 100 jM 06-BG for 1 h or 1 MM 06-BG for 24 h, commencing
1 h before alkylating treatment. Extended treatment with 1 jM 06-BG produced greater potentiation than
intermittent treatment with 100 jM 06-BG. Potentiation of temozolomide cytotoxicity increased linearly in
Mawi with each subsequent dosing: from 1.4-fold (day 1) to 4.2-fold (day 5) with continuous 1 jM 06-BG. In
contrast, no potentiation was observed in LS174T, a cell line that would appear to be 'tolerant' ofmethylation.
Potentiation of BCNU cytotoxicity increased in both cell lines with repeat dosing, although the rate of increase
was less than that observed with temozolomide and continuous 1 jgM 06-BG in Mawi. These results suggest
that repeat dosing of an AGT inhibitor and temozolomide may have a clinical role in the treatment of tumours
that exhibit AGT-mediated resistance.
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Temozolomide is an antineoplastic imidazotetrazinone that
demonstrated clinical activity in the treatment of high-grade
glioma, melanoma and mycosis fungoides during phase I
clinical evaluation (Newlands et al., 1992). Promising activity
has also been observed in both recurrent and newly
diagnosed high-grade astrocytomas in a preliminary phase
II study (O'Reilly et al., 1993). These responses were obtained
when a total dose of 750-1000 mg m-2 temozolomide was
fractionated into five equal doses and administered on
consecutive days (p.o., repeated at 4 weekly intervals).
Clinical activity of this compound is highly schedule
dependent: no activity is observed if the equivalent total
dose is administered as a single bolus.
The anti-tumour activity of temozolomide is attributed to
methylation of the accessible nucleophilic centres in DNA,
following chemical decomposition to 5-(3-methyl-triazeno)
imidazole-4-carboxamide (MTIC) at mildly alkaline pH, and
subsequent formation of a reactive methyldiazonium species
(Denny et al., 1994). Adduct formation at the 06 position of
guanine in DNA is often found to be the major determinant
of methylating agent cytotoxicity (Domoradzki et al., 1984;
Margison and O'Connor, 1990). It is assumed that 06-
methylguanine is cytotoxic by virtue of the cell's attempts to
process the methylated base during replication (Karran and
Bignami, 1992), a hypothesis supported by the demonstration
that 06-methylguanine can hinder DNA replication in vitro
(Ceccotti et al., 1993). During replication on a template
containing 06-methylguanine a non-semiconservative DNA
synthesis occurs (Karran et al., 1993), which correlates with
activation of the long patch mismatch repair pathway
(Holmes et al., 1990). This post-replicative repair mechanism
functions to maintain genomic fidelity and involves a specific
protein that acts as a binding factor for the recognition of
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GT mismatches (Jiricny et al., 1988; Griffin and Karran,
1993). It is suggested that when this repair process is targeted
to the strand directly opposite 06-methylguanine it is unable
to find a complementary base and thus results in long-lived
nicks in the DNA (Karran et al., 1993). These interruptions
in the daughter strands inhibit replication in the subsequent
S-phase (Plant and Roberts, 1971; Ceccotti et al., 1993) and
account for methylating cytotoxicity being only apparent
after at least two rounds of cell division (Catapano et al.,
1987). Since the anti-tumour activity of temozolomide is
thought to depend upon the formation of 06-methylguanine,
its clinical utility may be limited by the cytoprotective DNA
repair protein, 06-alkylguanine-DNA alkyltransferase
(AGT), which removes 06-alkylguanine adducts in a
stoichiometric, autoinactivating reaction (Pegg, 1983; Tano
et al., 1990). Resistance to temozolomide or MTIC readily
induced in vitro is attributed to this DNA repair process
(Hayward and Parsons, 1984; Catapano et al., 1987).
Depletion ofAGT, by pretreatment with the modified free
base 06-BG (a substrate analogue) has been widely examined
as a therapeutic strategy to circumvent AGT-mediated
resistance to the chloroethylnitrosourea BCNU (Friedman
et al., 1992; Mitchell et al., 1992; Dolan et al., 1993; Felker et
al., 1993; Gerson et al., 1993). BCNU has proven clinically
useful in the management of brain tumours and lymphomas
(Young et al., 1971; Edwards et al., 1980) but has limited
therapeutic efficacy because of intrinsic or acquired tumour
resistance (Walker and Hurwitz, 1970; Carter and Wasser-
man, 1976). This compound rapidly decomposes at
physiological pH to yield an alkylating chloroethyldiazo-
nium ion and a carbamoylating isocyanate (Montgomery et
al., 1967; Weinkam and Lin, 1979). The chloroethyldiazo-
nium species is capable of forming an 06-chloroethylguanine
adduct that can undergo intramolecular rearrangement to
produce an 06, N'-ethanoguanine residue. This residue is
relatively stable (Brent et al., 1987) but may eventually react
with cytosine in the complementary strand to form a 1-[N3-Potentiation of temozolomide cytotoxicity by 06-benzylguanine
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deoxycytidyl]-2-N'-[deoxyguanosinyl]-ethane interstrand cross-
link (Tong et al., 1982). It is this ability to cross-link DNA
that correlates with chloroethylnitrosourea cytotoxicity
(Lown et al., 1978; Bodell et al., 1985; Jiang et al., 1989).
AGT can prevent the formation of DNA cross-links not only
by removal of the initial 06-chloroethylguanine adduct but
also by reacting with the o6, N'-ethanoguanine intermediate
(Gonzaga et al., 1992). Because AGT can limit BCNU
cytotoxicity, there is often a good correlation between cellular
sensitivity to BCNU and AGT expression (Erickson et al.,
1980; Brent et al., 1985; Mitchell et al., 1992).
Methylating agents such as streptozotocin or temozolomide
have been examined in combination with the chloroethylni-
trosoureas as an alternative method of depleting AGT
(D'Incalci et al., 1991; Panella et al., 1992; Mitchell and
Dolan, 1993; Plowman et al., 1994). However, a methylating
agent itselfmay benefit from a protocol that involves depletion
of AGT by an inhibitor such as 06-BG. This study examined
the relationship between temozolomide cytotoxicity and AGT
expression and the potentiation of cytotoxicity by 06-BG.
These parameters were also examined with BCNU treatment
and comparisons made not only with single doses but also with
multiple dosing schedules to account for the schedule
dependency oftemozolomide cytotoxicity.
Materials and methods
Chemicals and drugs
Temozolomide was supplied by Dr J Catino, Schering-Plough
Research Institute, Kenilworth, NJ, USA, and BCNU
purchased from Bristol Myers Pharmaceuticals, Hounslow,
Middlesex, UK. 06-BG was a generous gift from Dr RC
Moschel, NCI-Frederick Cancer Research and Development
Center, Frederick, MD, USA and the [3H]methyl-labelled
DNA substrate for the assay of AGT was kindly supplied by
Dr GP Margison, Paterson Institute for Cancer Research,
Christie Hospital NHS Trust, Manchester, UK. All other
chemicals were purchased from Sigma, Poole, UK.
Cell culture
Seven human cell lines were examined within this study. The
colonic carcinoma cell line, Mawi, was established at Charing
Cross Hospital (Baer et al., 1993). StML-lla, a malignant
melanoma cell line (Zouboulis et al., 1989), was obtained
from Dr C Zouboulis, Department of Dermatology, The Free
University of Berlin, Germany. U87MG and U373MG
(glioblastoma astrocytoma), LS174T and HT29 (colon
carcinoma) and MCF-7 (breast adenocarcinoma) were
obtained from the European Tissue Culture Collection,
Porton Down, UK. Cell lines were grown as monolayers in
Dulbecco's modified Eagle medium (DMEM) (ICN Bio-
chemicals, High Wycombe, UK). Medium was supplemented
with 10% foetal calf serum (Gibco, Paisley, UK; inactivated
by heating at 56°C for 30 min), L-glutamine (2 mM), penicillin
(100 U ml-') and streptomycin (100 Mig ml-'). Cultures were
maintained in exponential growth at 37°C in a 5% carbon
dioxide / 95% humidified atmosphere. Cell doubling times
were determined to be approximately 15 h for Mawi and
HT29, 18 h for LS174T, 24 h for U87MG and U373MG,
26 h for StML- lla and 30 h for MCF-7.
Cytotoxicity evaluations were performed in 96-well
microtitre plates, with six wells per plate being used for
each drug concentration (±+06-BG) or a relevant control
(incubated with the corresponding vehicles).
For the measurement of AGT activity, LS174T, HT29,
Mawi and MCF-7 were plated in 75 cm3 flasks and U87MG,
U373MG and StML-I la in 175 cm3 flasks. Cells were
incubated for 48 h before a 1 h treatment of 06-BG
(100 gM; 0.5% ethanol in DMEM) or vehicle alone.
Following treatment cells were rinsed in phosphate-buffered
saline (PBS) (10 ml for 5-10 s) and the medium replenished.
Cells were reincubated for 1 or 24 h, harvested, frozen in liquid
nitrogen and then stored at -80°C before AGT determination.
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Cytotoxicity assay
Cytotoxicity was evaluated using the sulphorhodamine-B
(SRB) assay for protein (Skehan et al., 1990). The optimal
plating density was defined as that which enabled logarithmic
cell growth for a period of 8 days and produced an
absorbance of 1.0-1.5 absorbance units (AU) (k 492 nm)
when analysed by the SRB assay. This was predetermined for
each cell line in 96-well plates and found to be 1000 cells per
well for Mawi, 5000 cells per well for StML-1 la and MCF-7
and 2000 cells per well for all other cell lines studied. Cells
were plated and allowed to grow for 24 h before treatment.
In single dosing studies cells were preincubated for I h with/
without 06-BG (100 gM; 0.5% ethanol in DMEM) and the
medium then removed from all plates and replaced with that
containing either temozolomide [1- 1200 gM; 0.66% dimethyl
sulphoxide (DMSO) in DMEM] for 3 h or BCNU (0.5-300
gM; 0.19% ethanol in DMEM) for 1 h. Stock solutions of
temozolomide or BCNU were freshly prepared in DMSO or
ethanol and serial dilution into medium and addition to
plates accomplished within a period of 10 min to maintain
drug integrity. Following drug incubation the medium was
replenished with fresh drug-free medium and plates
reincubated for a further 7 days before assay. In multiple
dosing studies incubation with/without 06-BG followed by
treatment with either temozolomide or BCNU was repeated
at successive 24 h intervals. This was performed for a
maximum of 5 days to give a minimum 'recovery period' of
72 h. For comparison with the 100 MM 06-BG pretreatment
(1 h) multiple dosing studies were also conducted with a
1 MM 06-BG incubation, which was added 1 h before
temozolomide or BCNU, during drug incubation, and with
medium replenishment, thereby attaining continuous expo-
sure for 24 h.
IC50 values were interpolated by cubic spline regression
using a SLT 340 ATTC plate reader (SLT Instruments,
Austria) and Biolise software (Labtech International, East
Sussex, UK). Potentiation of temozolomide or BCNU
cytotoxicity by 06-BG was taken to be the ratio between
the IC50 value achieved without 06-BG pretreatment divided
by the IC50 value achieved with 06-BG pretreatment. Mean
interexperimental potentiation was calculated from three
independent experiments.
Assay of AGT activity
AGT activity was measured as removal of 06_
[3H]methylguanine from a [3H] methylated DNA substrate,
using the method of Lee et al. (1991). Briefly, cell extracts
were incubated with the substrate, after which the DNA was
precipitated with perchloric acid (PCA) and hydrolysed with
hydrochloric acid. The protein (containing methylated AGT)
was collected by centrifugation and counted at a counting
efficiency of 40%. Sp. act. measurements were made under
protein-limiting conditions, in which the activity was
proportional to the amount of extract added, using a
minimum of four points. The AGT activity of an extract
was expressed as fmol of [3H]CH3 transferred from the DNA
substrate per mg of protein or per yg of DNA. Protein was
determined by the method of Bradford (1976) and DNA
using a 33258 Hoechst dye method (Cesarone et al., 1987)
with a TKO 100 Dedicated Mini fluorometer (Hoefer
Scientific Instruments, San Francisco, CA, USA).
Results
Relationship between AGT activity and temozolomide or
BCNU cytotoxicity
A wide range of AGT activity was evident in the cell lines
studied; from <6 fmol mg ' protein for the glioblastoma cell
lines to > 700 fmol mg'- protein in the breast carcinoma cell
line MCF-7 (Table I). There is controversy as to whether the
relationship between AGT expressed as activity per cellular
00Potentiation of temozolomide cytotoxicity by 06-benzylguanine
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Table I AGT activity ± 06-BG, and cytoxicity data following single exposure to temozolomide or BCNU, with or without 06-BG
Cell line AGT AGT (fmol mg-' protein Temozolomidea IC50 (gM) BCNU" IC50 (gM)
(fmol ig'- DNA) Untreated 24 h after 06-BGc Without 06-BG With 06-BG Without 06-BG With 06-BG
MCF-7 16.33 ±1.74 721 ±47 68± 9.8 915± 73 581 ± 76 287± 39 128±16
Mawi 12.23± 1.59 535±28 41±2.6 987±30 778±53 230± 13 125±9
HT29 11.76±1.85 498±38 49±9.2 1039±28 872±33 172±10 117±17
LSl74T 5.71 ±0.68 197±15 18±0.7 899±39 815±22 112±12 44±6.6
STMIllA 2.73±0.31 113±28 4.3±0.6 386±9 287± 10 109±5.8 33±7.8
U373MG 0.24±0.09 5.6 ± 0.25 ND 46± 5.8 38±8.1 25.5±3.1 21±3.8
U87MG 0.22±0.05 2.5 ±0.49 ND 24± 5.5 26± 5.2 64± 6.8 59.6± 3.5
a 3 h incubation. b 1 h incubation. c 1 h incubation with 100 jM 06-BG. ND, not detectable. Cell lines were assayed for AGT activity as
described in Materials and methods without 06BG treatment (standardised to cellular DNA and protein) or 24 h after 06-BG treatment
(standardised to cellular protein). IC50 values were determined 7 days after a single treatment of temozolomide or BCNU, with/without 06-BG
pretreatment (100 gM for 1 h). Values represent the mean± s.e. with AGT activity mg protein determinations calculated from five separate
experiments, AGT activity jg-l DNA from at least three separate experiments and IC50 values from three separate experiments.
protein or cellular DNA is always linear, with standardisa-
tion to protein potentially being more variable because of
differences in cell size (Gerson et al., 1986; Citron et al.,
1991). Since the correlation between AGT activity normalised
to protein or DNA was linear in this study (Figure 1), it was
acceptable to routinely express AGT activity in terms of
cellular protein.
The relationship between the IC50 value obtained from a
single treatment of BCNU (1 h) and AGT activity was
relatively linear, such that cells with greater AGT were more
resistant to BCNU (Figure 2). One distinct exception was the
glioblastoma cell line U87MG, which had the lowest AGT
expression, but which did not display greatest sensitivity to
BCNU. The correlation between AGT activity and the IC50
value obtained from a single treatment of temozolomide (3 h)
was also linear for a number of cell lines (Figure 2), although
four cell lines with an AGT activity of between 200 and 750
fmol mg-' protein displayed almost equivalent resistance to
1uuu -
temozolomide, with IC50 values ranging from 899+39 to
1039+28 ,uM (Table I).
Depletion of AGT by 06-BG
Mawi cells, representative of a high AGT-expressing cell line,
were chosen to investigate the concentration and time
dependency of AGT depletion by treatment with 06-BG.
Exposure of Mawi cells to varying concentrations of 06-BG
for 1 h, followed by incubation in fresh medium for 1 h,
resulted in an inhibition profile that ranged from no
inhibition of AGT activity by 0.01 ,uM 06-BG, to >95%
inhibition by 1 jgM 06-BG (Figure 3). If cells were maintained
in fresh medium for 24 h following 06-BG treatment, partial
regeneration of AGT activity was observed; the AGT activity
of cells treated with 1 gM 06-BG being restored to 70% of
the untreated control value. To deplete over 90% of AGT
activity for 24 h a 1 h preincubation with 100 ,uM 06-BG was
required. A similar inhibition of AGT activity was also
demonstrated by 100 gM 06-BG in all other cell lines with >
100 fmol mg-' protein AGT (Table I). This concentration
also depleted AGT activity in U87MG and U373MG to a
level which was undetectable, and was selected for use in
sensitisation studies.
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Figure 1 Relationship between AGT activity expressed as a ratio
with total cellular protein or with cellular DNA. Cell lines in
order of increasing AGT activity are, U87MG, U373MG, StML-
1la, LS174T, HT29, Mawi and MCF-7. Data (mean values+
s.e.) are taken from Table I. The broken line represents linear
regression analysis, where r=0.996. Linear regression analysis of
data plotted on a linear/linear scale also gave an r-value of
>0.99.
100 1000
AGT (fmol mg-1 protein)
Figure 2 Relationship between AGT activity and IC50 value after
a single treatment with temozolomide (0) or BCNU (0). Cell
lines appear in order of increasing AGT activity as in Figure 1.
Each point represents a mean, with horizontal error bars
indicating the standard deviation of five separate AGT
measurements and vertical error bars the standard deviation of
three separate IC50 determinations.
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Potentiation of temozolomide or BCNU cytotoxicity by O6'
BG: single-dose schedule
No significant potentiation of temozolomide or BCNU
cytotoxicity was achieved by pretreatment with 06-BG in
the glioblastoma cell lines U87MG and U373MG. Potentia-
tion of cytotoxicity by 06-BG pretreatment is illustrated for
the remaining five cell lines in Figure 4. In each cell line,
potentiation of BCNU cytotoxicity always exceeded that
observed with temozolomide. Some proportionality between
AGT activity and the potentiation ofcytotoxicity was evident
in HT29, Mawi and MCF-7, although this correlation did
not extend to all cell lines. Variation in the potentiation of
BCNU cytotoxicity was greatest, with maximum potentiation
occurring in cell lines with an AGT activity of < 200 fmol
mg-' protein and > 700 fmol mg- protein, but with
substantially less potentiation being evident in cell lines with
100
80
> 60
40
20
c
intermediate AGT activity. It was also of interest to note the
variation between the potentiation of methylation and
chloroethylation cytotoxicity within the same cell line. This
was exemplified in LS174T, in which least potentiation of
temozolomide cytotoxicity was apparent, and yet maximal
potentiation of BCNU cytotoxicity was observed.
Potentiation of temozolomide or BCNU cytotoxicity by o6'
BG: multiple dosing schedule (days 1-5)
Two colorectal cell lines, a tumour type renowned for
being chemoresistant (Moertel, 1973; Redmond et al.,
1991), were chosen to evaluate potentiation following
repeat dosing with 06-BG and either temozolomide or
BCNU (Table II). LS174T was selected to determine
whether the lack of potentiation observed with 06-BG
and temozolomide on a single-dose schedule could be
circumvented by repeat dosing, whereas Mawi was
selected as being representative of a cell line in which
depletion of AGT clearly did potentiate temozolomide
cytotoxicity (Figure 4).
0
0
co
a)
0
0L
0.01 0.1 1 10 100
06-BG Concentration (gM)
Figure 3 Depletion of AGT activity in Mawi cells. Cells were
incubated for 1 h with 0.01- 100 gmM 06-BG and AGT activity
determined 1 h (S) and 24h (0) after medium replenishment.
Data points represent the mean of two separate experiments.
StML-lla LS174T HT29 Mawi MCF-7
Cell line
Figure 4 Potentiation of temozolomide (L]) and BCNU (V)
cytotoxicity by pretreatment with 06-BG. 'Potentiation' was
defined as the increase in cytotoxicity afforded by a h
pretreatment with 100 PM 06-BG. Each bar represents the mean
potentiation+s.e. from three independent experiments.
Table II Cytoxicity data following repeate exposure to temozolomide or BCNU, with or without 06-BG
IC50 (PM)
Cycles of treatment (days)
Cell line Drug treatment 06-BG treatment 1 2 3 4 5
Mawi Temozolomide None 967+45 526 ±25 425+ 19 375± 7.8 353± 9.0
(3 h) Pretreatment (100 /IM; 1 h) 654± 135 305±52 215+ 1.8 182+2.9 156±9.7
Continuous (1 gM) 774±78 278+36 153+ 17 112±17 87+ 15
Mawi Temozolomide None 242± 10 165+6.8 142+9.2 126±8.1 119+9.9
(3 h) Pretreatment (100 gM; 1 h) 125+9.2 80+4.6 61+ 1.0 51+5.3 46+4.8
Continuous (1 gM) 90+1.5 59+2.8 41+2.4 35+4.6 27.5+3.7
LS174T Temozolomide None 918+ 77 524+ 92 374+48 318+ 38 328+49
(3 h) Pretreatment (100 gM; 1 h) 784+23 488+40 344+47 326+46 289+ 31
Continuous (1 jM) 707 + 86 417+ 69 277+ 22 280+ 24 232± 32
LS174T BCNU None 112+ 5.1 67+6.1 50+ 4.5 38+ 5.0 32+ 6.7
(1 h) Pretreatment (100 /iM; 1 h) 50+3.0 28+2.8 20+0.7 13±2.6 13±10
Continuous (1 gM) 26±2.5 13±1.0 8.8±1.3 5.9+0.5 6.7+1.1
Mawi or LS174T cells recieved between one and five treatments (one every 24 h) oftemozolomide or BCNU, with/without either 100 MM 06-BG
(1 h) or 1 PM 06-BG (24 h) commencing 1 h before alkylating treatment. Cells were incubated in drug-free medium following treatment and
cytotoxicity assessed 8 days afterplating. All values represent mean ±s.e., with IC50 values for temozolomide or BCNU alonebeingcalculated from
six separate experiments and IC50 values involving an 06-BG treatment from three separate experiments,
vJPotentiation of temozolomide cytotoxicity by 06-benzylguanine
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Figure 5 Potentiation of temozolomide or BCNU cytotoxicity by
O -BG with repeat dosing in Mawi. Mawi cells received between
one and five treatments (one every 24h) of (a) temozolomide or
(b) BCNU, with/without 100 MM 06-BG for 1 h (-) or 1 MM 06_
BG for 24h (0) commencing h before alkylating treatment.
'Potentiation' was defined as the relative increase in cytotoxicity
afforded by the particular 06-BG treatment. Each data point
represents the mean potentiation+ s.e. from three independent
experiments. Each point without an error bar had a s.e. smaller
than the data symbol.
The progressive reduction in mean IC50 values, produced by
multiple doses of temozolomide or BCNU, was consistently
less with each additional drug treatment (Table II). This
phenomenon may be attributable to the development of
resistance or to the variation in post-treatment incubation
time, even though the shortest recovery period (72 h) would
have accommodated at least four cell divisions of Mawi or
LS174T. The mean intraexperimental potentiation of
temozolomide cytotoxicity was found to increase linearly
between days 1 and 5 (Figure 5a), which would suggest that
this assay did have the capacity to measure relative changes
in cytotoxicity produced by treatment with 06-BG. In Mawi,
potentiation of temozolomide cytotoxicity increased from
1.5+0.2- to 2.2+0.1-fold (days 1 to 5, mean+s.e.) with 100
,uM 06-BG pretreatment, whereas BCNU cytotoxicity
increased from 1.8+0.1- to 2.7+0.1-fold (Figure 5).
Continuous 1 ,uM 06-BG markedly increased the potentia-
tion of temozolomide cytotoxicity (1.4+0.1- to 4.4+0.6-
Figure 6 Potentiation of (a) temozolomide or (b) BCNU
cytotoxicity by 06-BG with repeat dosing in LS174T. Symbols
are as for Figure 5.
fold) and also further increased BCNU cytotoxicity,
although by relatively less (2.6+0.2- to 3.8 +0.3-fold). No
appreciable potentiation of temozolomide cytotoxicity could
be achieved in LS174T by repeat dosing with 06-BG
treatment (Figure 6a), even though potentiation of BCNU
cytotoxicity was greatest in this cell line (Figure 6b).
Increasing potentiation of BCNU cytotoxicity was con-
ferred by repeat dosing in both cell lines but was often
limited to the first four doses. However, even when
comparisons were restricted to between days 1 and 4, the
net increase in potentiation of temozolomide cytotoxicity
(mean+s.e.) afforded by repeat dosing with continuous 1
uM 06-BG was 2.5+0.3-fold in Mawi, which exceeded that
observed with BCNU in either Mawi (0.6+0.1-fold) or
LS174T (1.6+0.4-fold).
Discussion
This study was performed to contrast the potentiation of
therapeutic methylation and chloroethylation by AGT
depletion, and thereby determine whether the combination
of temozolomide with 06-BG is worthy of consideration for
clinical development.
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The relatively greater cytotoxicity of BCNU is a
consequence of the DNA cross-link, a lesion which is highly
toxic by virtue ofits ability to obstruct RNA transcription and
DNA replication (Erickson et al., 1980; Pieper et al., 1989)
and which is responsible for the severe myelosuppression that
often accompanies clinical usage of the chloro-ethylnitrosour-
eas. In contrast, methylating cytotoxicity is comparatively less:
temozolomide is tolerated at an approximately 10-fold greater
dose than its chloroethylating analogue mitozolomide (New-
lands et al., 1985; Newlands et al., 1992).
A linear correlation between AGT activity and chloro-
ethylnitrosourea cytotoxicity has been described in a number
of studies (Brent et al., 1985 Gerson et al., 1992; Sarker et al.,
1993; ) and increasing evidence suggests that a similar
relationship may also exist with chemotherapeutic methyla-
tors such as MNNG (Scudiero et al., 1984), MTIC (Gibson
et al., 1986) or temozolomide (Tisdale, 1987). The results of
this study support the existence of a correlation between
temozolomide cytotoxicity and AGT activity, although
exceptions were apparent. In particular, the colorectal cell
line LS174T was as resistant to temozolomide as cell lines
with 2.5- to 3.5-fold greater AGT activity. That resistance to
temozolomide in this cell line was not dependent upon AGT
activity was confirmed with both single and repeat dosing
studies, in which depletion of AGT by 06-BG did not afford
an increase in temozolomide cytotoxicity (Figures 4 and 6).
This 'tolerance' to methylation may be attributable to loss of
the mismatch repair pathway, which would normally generate
DNA strand breaks and thereby induce cell death during the
futile attempt to find a complementary base for o6-
methylguanine (Griffin et al., 1994). Defects in DNA
mismatch binding are relatively common in human color-
ectal adenocarcinoma cell lines (Parsons et al., 1993; Umar et
al., 1994; Branch et al., 1995) and result in DNA
microsatellite instability (Branch et al., 1993), a phenomenon
also apparent in LS174T (Shibata et al., 1994). Mismatch
recognition is known to involve a heterodimer (Palombo et
al., 1994) consisting of two homologues of the Escherichia
coli MutS protein (Su and Modrich, 1986): hMSH2 (Fishel et
al., 1993) and GTBP/pl60 (Drummond et al., 1995; Palombo
et al., 1995). This structure interacts with another hetero-
dimer consisting of hPMS2 and hMLH1 proteins (Li and
Modrich, 1995), which are homologues of the E. coli MutL
repair protein (Grilley et al., 1989). Thus, although extracts
from LS174T have been found to exhibit normal GT
mismatch binding in a bandshift assay (Branch et al.,
1995), a binding defect may exist within the interaction of
the human MutS complex with a MutL homologue. The
many additional instances in which methylating cytotoxicity
and AGT activity appear unrelated (Baker et al., 1979;
Scudiero et al., 1984; Goldmacher et al., 1986; Goth-
Goldstein, 1987; Branch et al., 1993; Griffin and Karran,
1993; Kat et al., 1993) could also be possibly accounted for
by a defect in any one of five mismatch repair genes
(Papadopoulos et al., 1995).
It should also be noted that the relationship between AGT
activity and BCNU cytotoxicity is not always linear and that
tumour models besides the glioblastoma U87MG in this
study (Figure 3) have been known to demonstrate non-AGT-
mediated resistance to chloroethylating agents (Dolan et al.,
1991; Silber et al., 1992). Alternative mechanisms of
resistance to BCNU include the activity of cellular
glutathione S-transferases and glutathione levels, which may
quench chloroethylated DNA monoadducts (Ali-Osman,
1989) or directly inactivate BCNU by denitrosation (Smith
et al., 1989). This latter reaction can also be catalysed by the
cytochrome P450 mono-oxygenase system (Potter and Reed,
1983). In addition, polyamine metabolism has been
implicated in resistance to some alternative component of
BCNU cytotoxicity, which is independent of cross-link
formation (Seidenfeld et al., 1987).
Potentiation of a single dose of chloroethylating or
methylating agent by AGT depletion in vitro usually results
in an enhancement of cytotoxicity of up to 5-fold, although
potentiation of 10- to 12-fold has been documented (Marathi
et al., 1993; Dolan et al., 1985a; Aida et al., 1987; Gerson et
al., 1988). It is suggested that this potentiation is dependent
upon the level ofAGT expression, with no potentiation being
evident in cells with little AGT activity (Gerson et al., 1988;
Dolan et al., 1991; Baer et al., 1993; Plowman et al., 1994).
The results obtained with the glioblastoma cell lines, U87MG
and U373MG, would support this finding, since the AGT
activity of these cell lines was less than 6 fmol mg-' protein
and no potentiation of BCNU or temozolomide cytotoxicity
could be achieved by pretreatment with 06-BG (Table I).
However, the enhancement of temozolomide or BCNU
cytotoxicity in all other cell lines did not correlate with AGT
activity (Figure 4). This observation could not be accounted
for by differences in cell doubling time and may imply that
alternative resistance mechanisms are induced following AGT
depletion. DNA alkylation may also produce perturbations of
the cell cycle, which could conceivably affect the rate of AGT
regeneration. This would have a more pronounced effect on
the potentiation oftemozolomide, not only because the repair
protein has a greater affinity for 06-methyl adducts than for
06-chloroethyl adducts (Pegg et al., 1984; Brent, 1986) but
also because post-replicative AGT regeneration will be of
importance in regulating the cytotoxicity of methylation,
which is dependent upon multiple rounds of cell division
(Catapano et al., 1987). That the potentiation of temozolo-
mide cytotoxicity following a single 06-BG treatment was
always less than that observed with BCNU (Figure 4) may
partly be attributable to the de novo synthesis of AGT
following 06-BG treatment but is also likely to be a
consequence of the greater toxicity of the DNA cross-link.
It is probable that the schedule-dependent activity of
temozolomide is related to progressive AGT depletion, with
each additional exposure to the drug increasing the retention
of 06-methylguanine adducts (Lee et al., 1994). Thus it was
not surprising to find that potentiation of temozolomide
cytoxicity by an AGT inhibitor should increase with repeat
dosing (Figure Sa). The maximal potentiation of temozolo-
mide cytotoxicity observed in this study, following five
consecutive doses, was 4- to 5-fold, which is in contrast to
the 300-fold potentiation reported in a similar preliminary
experiment (Baer et al., 1993). However, the results of this
latter investigation would seem extremely unlikely, given the
magnitude of potentiation reported in the rest of the
literature.
Extended 1 MM 06-BG treatment was clearly more
efficacious than intermittent 100 JM 06-BG (1 h pretreat-
ment every 24 h) in enhancing either BCNU or temozolomide
cytotoxicity on five repeat doses (Figures 5 and 6b). That
optimal sensitisation to BCNU is dependent upon prolonged
depletion of AGT would correlate with the findings of
Marathi et al. (1994). However, the regeneration of AGT
following repeat dosing of 100 gmM 06-BG would be expected
to be marginal, given that a single treatment inhibits AGT by
>90% for 24 h (Table I). These results emphasise that
relatively low levels ofAGT can have profound effects on the
cytotoxicity of methylating and chloroethylating agents.
Although the 06-BG treatments used in this study were
not growth inhibitory, continual exposure to 06-BG alone for
a period of 5 days did result in an IC50 value of 35-40 /iM in
cell lines with an AGT activity as diverse as that of Mawi
(>500 fmol mg-' protein) and U87MG (<3 fmol mg-
protein) (data not shown). This non-specific toxicity should
be kept in mind when considering the use of extended
depletion studies, since the base analogues on single
administration are generally considered to be non-toxic
(Dolan et al., 1985b). Hence, toxicological considerations
may also be important in the selection of inhibitors, besides
the capacity to deplete AGT and compound solubility.
One potential hazard associated with a potentiation of
DNA methylation is the possibility that mutagenesis will also
be enhanced, since the mispairing of 06-methylguanine in
replication may result in G C to A T transitions (Yang et al.,
1994; Mitra et al., 1989). Correlations between mutagenesis
and AGT activity have previously been demonstrated (Liu et
al., 1994; Yarosh, 1985), which suggests that the probabilityPotentiation of temozolomide cytotoxicity by 06-benzylguanine
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ofcarcinogenesis may also be increased if a methylating agent
is combined with 06-BG. This may also apply to a
combination of BCNU and 06-BG, since BCNU can form
the carcinogenic lesion 6-(,B-hydroxyethyl)guanine (Tong et
al., 1981). Carcinogenicity will, however, depend upon a
number of kinetic factors such as the level of cell
proliferation and the possibility that AGT regeneration
rates may vary in different tissues (Dolan et al., 1988).
Whether such parameters will severely limit the use of 06-BG
as a therapeutic adjuvant is unclear, although the risk of
inducing a secondary malignancy may be outweighed by the
potential to significantly improve patient survival.
The fact that temozolomide does show clinical activity and
is well tolerated (up to 6 weeks continuous administration in
the current phase I study) suggests that a clinical
combination of temozolomide with 06-BG may be preferred
to a regimen involving BCNU and 06-BG, simply because
the chloroethylnitrosoureas are more inherently toxic.
Although 06-BG may exacerbate the relatively mild
myelosuppression produced by temozolomide (Fairburn
et al., 1995) this could, if necessary, be managed by
autologous bone marrow infusion and the administration of
haematopoietic growth factors. It is also possible that the
gene for AGT (Tano et al., 1990) could be transfected into
bone marrow cells before infusion and thereby confer greater
haematological resistance to such therapy.
In conclusion, this study reinforces the importance of
AGT as a determinant of methylating and chloroethylating
agent cytotoxicity but also emphasises that alternative
mechanisms of resistance may equally regulate sensitivity to
these compounds. It also suggests that the combination of
temozolomide with an inhibitor of AGT may have a clinical
role in the treatment of tumours that exhibit AGT-mediated
resistance, when administered via a repeat dosing schedule.
Abbreviations
Temozolomide, 8-carbamoyl-3-methylimidazo[5, 1-d]-1,2,3,5-tetra-
zine-4(3H)-one, also known as NSC 362856, CCRG 81045 and
SCH 52365; AGT, 06-alkylguanine-DNA alkyltransferase (EC
2.1.1.63); MTIC, 5-(3-methyl-1-triazeno)imidazole-4-carboxamide;
BCNU, 1,3-bis(2-chloroethyl)-nitrosourea (Carmustine); 06-BG,
06-benzylguanine; DMSO, dimethyl sulphoxide; PBS, phosphate-
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